ReviewWorld journal of gastroenterology2014
Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.World journal of gastroenterology · 2016Pooled it
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Novel anti-virulence strategy againstFrontiers in microbiology · 2026Article
- Potential Unnecessity of Bismuth in Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori Infection.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Protocatechuic acid, the main effective monomer in Wuqi Powder, can inhibit gastric ulcers induced by acetic acid andAmerican journal of translational research · 2023Article
- Prevalence of antibiotic resistance ofAmerican journal of translational research · 2022Article
- The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.Frontiers in pharmacology · 2022Review
- The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance.Research (Washington, D.C.) · 2020Review
- Phytochemicals inInternational journal of molecular sciences · 2018Review
- Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis.Microbiology and molecular biology reviews : MMBR · 2018Review
- Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management.Radiology and oncology · 2018Article
- World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.Journal of gastroenterology · 2018Review
- Antimicrobial susceptibility testing before first-line treatment forWorld journal of gastroenterology · 2017Observational
- A Comparison between Hybrid and Concomitant Regimens forMiddle East journal of digestive diseases · 2016Article
- Hybrid Therapy Regimen for Helicobacter Pylori Eradication.Chinese medical journal · 2016Review
- Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China.Gastroenterology research and practice · 2016Article
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of duration, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous therapy), which have gained interest lately. We also revise evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.